Pharmacyclics, LLC

265 articles about Pharmacyclics, LLC

• Pharmacyclics Release: Ibrutinib (IMBRUVICA) Improves OutcomesFor Pancreatic Ductal Adenocarcinoma In Mouse Models

  4/20/2015

• AbbVie Extends Exchange Offer To Acquire Pharmacyclics

  4/20/2015

• Pharmacyclics Release: New Longer-Term IMBRUVICA (ibrutinib) Data Show High Response Rates In Patients With Waldenstrom's Macroglobulinemia

  4/9/2015

• Pharmacyclics Release: Solid Tumor Study Investigating Ibrutinib (IMBRUVICA) In Combination With Anti-PD-L1 Antibody (MEDI4736) Commences In Patients With Relapsed/Refractory Non-Small Cell Lung, Breast And Pancreatic Cancers

  4/1/2015

• AbbVie Elated as Pharmacyclics's Imbruvica Shines in Combo Trial

  3/20/2015

• Pharmacyclics Release: New ibrutinib (IMBRUVICA) Data To Be Presented At American Association for Cancer Research Meeting

  3/19/2015

• Pharmacyclics Release: Independent Data Monitoring Committee Unanimously Recommends Unblinding Of IMBRUVICA (Ibrutinib) Phase III Combination HELIOS Trial Based On Interim Analysis Showing Significant Improvement In Progression-Free Survival In Patients W

  3/17/2015

• Inside The $21 Billion Bidding War For Pharmacyclics

  3/6/2015

• AbbVie Overpaid in Pharmacyclics Deal, For Only 50% Rights to Imbruvica: Analyst

  3/6/2015

• AbbVie Outbids Johnson & Johnson and Lands Pharmacyclics for $21 Billion

  3/6/2015

• Pharmacyclics Release: In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody

  3/2/2015

• Bay Area's Pharmacyclics Mulls Possible $18 Billion Sale; Johnson & Johnson,Novartis AG Interested

  3/2/2015

• Market Analysis: Pharmacyclics Sale Good Idea if Buyer Understands Imbruvica Potential, Says Analyst

  2/27/2015

• Pharmacyclics, Inc. Reports Fourth Quarter And Full Year 2014 Financial Results And Provides Business Updates

  2/18/2015

• Pharmacyclics, Inc. Release: IMBRUVICA (ibrutinib) Treatment Shows Efficacy And Tolerability In Heavily Treated Chronic Lymphocytic Leukemia Patients Following Allogeneic Stem Cell Transplant

  2/17/2015

• Pharmacyclics, Inc. Announces Conference Call To Discuss Fourth Quarter And Full Year 2014 Financial Results

  2/12/2015

• Pharmacyclics, Inc. Announces Preliminary 2014 U.S. Net Product Revenue Results And 2015 U.S. Net Product Revenue Outlook

  1/13/2015

• Pharmacyclics, Inc. Release: IMBRUVICA® (ibrutinib) Data Demonstrates Efficacy In Previously Untreated And Relapsed/Refractory High-Risk Chronic Lymphocytic Leukemia Patients

  1/5/2015

• Pharmacyclics, Inc. Announces Update On IMBRUVICA® (Ibrutinib) Waldenstrom's Macroglobulinemia (WM) Submission

  12/22/2014

• Pharmacyclics, Inc. Named 2014 Outstanding Company By BayBio (Bay Area Bioscience Association)

  12/12/2014